Clinical trial · Interventional
Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
Safety and Efficacy of Adjuvant Therapy of Autologous Dendritic Cells and Allogenic Dendritic Secretomes for Patients With Advanced Nasopharyngeal Cancer
NCT05261750CI-TRIAL-00104073active not recruitingPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to determine the safety and potential of dendritic cells therapy and secretomes therapy for advanced nasopharyngeal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Nasopharyngeal Cancer | Malignant Nasopharyngeal Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy) | Biological | — | UNRESOLVED |
| Combination of Auto DC and Allo-Dendritic Cell-Secretome (Allogeneic Dendritic Cell-Secretome as Adjuvant Therapy) | Biological | — | UNRESOLVED |
| Placebo (Aqua Pro-Injection) | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- type
- PLACEBO_COMPARATOR
- label
- Placebo (Aqua Pro-Injection)
- description
- Subject will given 2 times injection of Aqua Pro-Injection via intramuscular (interval 2 days).
- interventionNames
- Other: Placebo (Aqua Pro-Injection)
- type
- EXPERIMENTAL
- label
- Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy)
- description
- Subject will given injection of Aqua Pro-Injection via intramuscular, two days after followed by Auto-DC via intramuscular.
- interventionNames
- Biological: Auto-DC (Autologous Dendritic Cell as Adjuvant Therapy)
- type
- EXPERIMENTAL
- label
- Combination of Auto DC and Allo-DC-Secretome
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who tested positive EBV and confirmed suffering advanced nasopharyngeal cancer * Patients who have partial response or stable disease or progressive disease after performed standard therapy (radiology or chemoradiation) based on RECIST * Did not take traditional medicine in the last 2 months. * Patients can understand the nature of the study and willing to sign informed consent * Patients who received standard medical (radiology or chemoradiation) up to one additional therapy in the last 1 month. Exclusion Criteria: * Patients who are pregnant, planning to pregnant, or breastfeeding * Patients assessed to require chemoradiation during this study * Patients who get complete score after undergo standard therapy (radiology or chemoradiation) based on the RECIST * Patients who have autoimun reaction, eczema, allergy or allergy history, and anaphylaxis * Patients who have creatinin clearance result \<40 ml/min, bilirubin serum \>1.5x above normal, SGPT-SGOT \>5x above normal * Patients on immunosuppressive medications, such as corticosteroids * Patients who undergo Major thoracic or abdominal operation * Patients on high medical risk condition due to uncontrolled infection * Patients who diagnosed positive of Hepatitis B, Hepatitis C or Human Immunodeificiency virus (HIV) * Patients who have concurrent congestive heart failure history and other heart disease * Patients who have health conditions assessed by the doctor in charge cannot be included in this clinical trial * Patients who refuse or did not participate in part or all of the research process
References
Publications (0)
Data not yet available
No reference posted for this study.